Compare BigBearai Holdings Inc (BBAI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Pfizer Inc — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.48B), while Pfizer Inc trades at $24.55 (market cap $138.21B). The key difference: Pfizer Inc is far larger — about 93.4× BigBearai Holdings Inc's market cap, and Pfizer Inc pays a 7.09% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | PFE | |
|---|---|---|
Market Cap | $1.48B | $138.21B |
Sector | Technology | Health |
52-Week High | $8.91 | $28.56 |
52-Week Low | $3.05 | $23.29 |
Enterprise Value | $1.16B | $188.87B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.08, down 5.81% in the past 24 hours, with a bearish technical signal from moving averages. The company reported revenue of $127.67M in 2025 but a net loss of $293.91M, reflecting a negative net margin of -226.69%. Recent news highlights AI growth opportunities in defense and airport security, yet profitability challenges persist.
Outlook remains cautious due to ongoing losses and negative cash flow from operations. Investment opportunities include backlog growth and debt reduction, but risks include high SG&A expenses and reliance on government contracts. Analyst consensus is mixed with 75% hold ratings, indicating uncertainty about near-term performance.
Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.
The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
